Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.880 EUR | +0.35% |
|
-3.36% | -18.87% |
Jan. 14 | BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2024 | CI |
Dec. 12 | BRAIN Biotech AG - Analyst/Investor Day |
Fiscal Period: September | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 39.06M | 39.22M | 50.3M | 56.22M | 55.5M | |||||
Other Revenues, Total | - | - | - | - | - | |||||
Total Revenues | 39.06M | 39.22M | 50.3M | 56.22M | 55.5M | |||||
Cost of Goods Sold, Total | 17.46M | 17.4M | 22.69M | 25.8M | 24.94M | |||||
Gross Profit | 21.6M | 21.82M | 27.61M | 30.42M | 30.56M | |||||
Selling General & Admin Expenses, Total | 19.26M | 20.5M | 23.06M | 23.34M | 26.36M | |||||
Depreciation & Amortization - (IS) | 3.93M | 4.01M | 4.34M | 4.65M | 4.82M | |||||
Other Operating Expenses | 5.04M | 4.69M | 6.59M | 7.99M | 8.39M | |||||
Other Operating Expenses, Total | 28.24M | 29.21M | 33.99M | 35.98M | 39.58M | |||||
Operating Income | -6.63M | -7.39M | -6.38M | -5.56M | -9.01M | |||||
Interest Expense, Total | -673K | -521K | -529K | -858K | -1.94M | |||||
Interest And Investment Income | 14K | 11K | 4K | 4K | - | |||||
Net Interest Expenses | -659K | -510K | -525K | -854K | -1.94M | |||||
Income (Loss) On Equity Invest. | -2.39M | -1.72M | -2.43M | -1.49M | -498K | |||||
Currency Exchange Gains (Loss) | -61K | -35K | 118K | -61K | -109K | |||||
Other Non Operating Income (Expenses) | 676K | 3.98M | 281K | 84K | 518K | |||||
EBT, Excl. Unusual Items | -9.07M | -5.68M | -8.93M | -7.88M | -11.04M | |||||
Restructuring Charges | -869K | - | - | - | - | |||||
Merger & Related Restructuring Charges | -222K | -313K | -476K | -279K | - | |||||
Impairment of Goodwill | -11K | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | 577K | 2.36M | 541K | - | |||||
Gain (Loss) On Sale Of Assets | - | - | 650K | - | - | |||||
Asset Writedown | -408K | - | - | - | - | |||||
Insurance Settlements | 2K | - | - | - | - | |||||
Other Unusual Items | 630K | 1.14M | 239K | 134K | 53K | |||||
EBT, Incl. Unusual Items | -9.94M | -4.28M | -6.16M | -7.49M | -10.99M | |||||
Income Tax Expense | -927K | 403K | 176K | 625K | 111K | |||||
Earnings From Continuing Operations | -9.02M | -4.68M | -6.34M | -8.11M | -11.1M | |||||
Net Income to Company | -9.02M | -4.68M | -6.34M | -8.11M | -11.1M | |||||
Minority Interest | -667K | -292K | -249K | -165K | -27K | |||||
Net Income - (IS) | -9.68M | -4.97M | -6.59M | -8.28M | -11.13M | |||||
Net Income to Common Incl Extra Items | -9.68M | -4.97M | -6.59M | -8.28M | -11.13M | |||||
Net Income to Common Excl. Extra Items | -9.68M | -4.97M | -6.59M | -8.28M | -11.13M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.52 | -0.25 | -0.3 | -0.38 | -0.51 | |||||
Basic EPS - Continuing Operations | -0.52 | -0.25 | -0.3 | -0.38 | -0.51 | |||||
Basic Weighted Average Shares Outstanding | 18.66M | 19.94M | 21.85M | 21.85M | 21.85M | |||||
Net EPS - Diluted | -0.52 | -0.25 | -0.3 | -0.38 | -0.51 | |||||
Diluted EPS - Continuing Operations | -0.52 | -0.25 | -0.3 | -0.38 | -0.51 | |||||
Diluted Weighted Average Shares Outstanding | 18.66M | 19.94M | 21.85M | 21.85M | 21.85M | |||||
Normalized Basic EPS | -0.34 | -0.19 | -0.27 | -0.23 | -0.32 | |||||
Normalized Diluted EPS | -0.34 | -0.19 | -0.27 | -0.23 | -0.32 | |||||
Supplemental Items | ||||||||||
EBITDA | -3.56M | -4.1M | -3.27M | -2.39M | -5.73M | |||||
EBITA | -4.73M | -5.7M | -4.87M | -3.96M | -7.56M | |||||
EBIT | -6.63M | -7.39M | -6.38M | -5.56M | -9.01M | |||||
EBITDAR | -2.61M | -3.11M | -1.89M | -1.05M | -4.47M | |||||
Total Revenues (As Reported) | 39.24M | 40.73M | 53.07M | 57.14M | 55.52M | |||||
Effective Tax Rate - (Ratio) | 9.32 | -9.42 | -2.85 | -8.35 | -1.01 | |||||
Total Current Taxes | -533K | 169K | 226K | 168K | 96K | |||||
Total Deferred Taxes | -394K | 234K | -50K | 457K | 15K | |||||
Normalized Net Income | -6.33M | -3.84M | -5.83M | -5.09M | -6.93M | |||||
Interest on Long-Term Debt | 99K | 98K | 103K | 162K | 333K | |||||
Non-Cash Pension Expense | 26K | 24K | 26K | 42K | 38K | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 5.79M | 5.38M | 4.87M | 4.98M | 6.24M | |||||
Net Rental Expense, Total | 946K | 993K | 1.38M | 1.34M | 1.26M | |||||
Imputed Operating Lease Interest Expense | 499K | 338K | 529K | 571K | 1.06M | |||||
Imputed Operating Lease Depreciation | 447K | 655K | 852K | 770K | 196K | |||||
Maintenance & Repair Expenses, Total | 434K | 585K | 625K | 591K | 634K | |||||
Stock-Based Comp., SG&A Exp. (Total) | 629K | 989K | 1.38M | 714K | 894K | |||||
Total Stock-Based Compensation | 629K | 989K | 1.38M | 714K | 894K |